



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl

Modifications of *Bordetella bronchiseptica* core lipopolysaccharide influence immune response without affecting protective activity



Federico Sisti^{a,*}, Julieta Fernández^a, Andrés Cordero^a, Adriana Casabuono^b, Alicia Couto^b, Daniela Hozbor^a

^aInstituto de Biotecnología y Biología Molecular, CCT La Plata CONICET, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 47 y 115, 1900 La Plata, Argentina

^bCIHIDECAR, Departamento de Química Orgánica, Facultad de Cs Exactas y Naturales, Universidad de Buenos Aires, 1428 Bs. As., Argentina

ARTICLE INFO

Article history:

Received 4 October 2016

Revised 18 December 2016

Accepted 19 December 2016

Available online 21 December 2016

Keywords:

Lipopolysaccharide

Bordetella

Glycosyltransferase

ABSTRACT

Bordetella bronchiseptica produces respiratory disease primarily in mammals including humans. Although a considerably amount of research has been generated regarding lipopolysaccharide (LPS) role during infection and stimulating innate and adaptive immune response, mechanisms involved in LPS synthesis are still unknown. In this context we searched in *B. bronchiseptica* genome for putative glycosyltransferases. We found possible genes codifying for enzymes involved in sugar substitution of the LPS structure. We decided to analyse *BB3394* to *BB3400* genes, closed to a previously described LPS biosynthetic locus in *B. pertussis*. Particularly, conservation of *BB3394* in sequenced *B. bronchiseptica* genomes suggests the importance of this gene for bacteria normal physiology. Deletion of *BB3394* abolished resistance to naive serum as described for other LPS mutants. When purified LPS was analyzed, differences in the LPS core structure were found. Particularly, a GalNA branched sugar substitution in the core was absent in the LPS obtained from *BB3394* deletion mutant. Absence of GalNA in core LPS alters immune response *in vivo* but is able to induce protective response against *B. bronchiseptica* infection.

© 2016 Published by Elsevier Ltd.

Bacterial surface polysaccharides are known to contribute to bacterium–host interaction, including symbiotic and pathogenic relationships.¹ Among these polysaccharides, the lipopolysaccharide (LPS) is the major component of the outer membrane of gram-negative bacteria and consists of highly variable as well as conserved segments.² In extremely small amounts LPS possess potent bioactivities initiating the morbidity and mortality associated with Gram-negative sepsis as well as the modulation of a myriad of host innate inflammatory responses. Interestingly, specific synthetic alterations within conserved segments of LPS were shown to be recognized not only by host cells but were also capable of blocking or down-regulating the response to other LPS

forms normally associated with robust innate cell activation.³ In fact, structural heterogeneity of LPS of certain pathogenic bacteria like *Helicobacter pylori*, was shown to result in differential and altered innate host cell responses.^{4–7}

Bordetella bronchiseptica can infect a variety of mammals including humans. Other authors and ourselves previously showed that *B. bronchiseptica* expresses a LPS that plays an essential role in host interaction, being critical for the early clearance of the bacteria.⁸ Like in other pathogens, *B. bronchiseptica* isolates from human patients presented LPS modifications.⁹ Purified *B. bronchiseptica* LPS presents after electrophoresis in polyacrylamide gels a pattern of three bands. Faster migrating band is called B and comprises a lipid A domain and a branched-chain core oligosaccharide. Band B is further modified by the addition of a complex trisaccharide called band A (band B plus trisaccharide). In addition, a pentasaccharide links the O antigen consisting in a homopolymer of 2, 3-dideoxy-2,3-di-N-acetyl galactosaminuronic acid to the core-trisaccharide region.¹⁰ The complete structure, (band B plus band A plus O antigen) is presented as the slower migrating band. Mutation of genes involved in core synthesis usually abolish further LPS synthesis.^{11,12} LPS structure in these mutants is called deep rough because of mutant colony morphology and is visualized in polyacrylamide gels as a single fast migrating band.

Abbreviations: Kdo, 3-deoxy-D-manno-octulosonic acid; Hep, Heptose, 1-glycero-D-manno-heptose; GlcA, glucuronic acid; GlcN, glucosamine; GlcNAc, N-acetylglucosamine; FucN, Fuc2NAc4N, 2-acetamido 4-amino 2,4,6-trideoxy-galactose; Man2,3NAcA, 2, 3-diacetamido-2,3-dideoxymannuronic acid; GlcNAc, N-acetylglucosamine; Man2, 3NAcAN, 2,3-diacetamido-2,3-dideoxymannuronamide; GalNAc3NAcA, 2,3-diacetamido-2,3-dideoxygalacturonic acid; GlcNAc3NAcAN, 2,3-diacetamido-2,3-dideoxyglucuronamide; Lac type, 2-Nacetyl, 3-Nformyl, 4N-(2-methoxypropionyl)-2,3,4-triamino 2,3,4-trideoxy- α -galacturonamide.

* Corresponding author at: Instituto de Biotecnología y Biología Molecular, CCT La Plata CONICET, Departamento de Ciencias Biológicas, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Calles 49 y 115, 1900 La Plata, Argentina.

E-mail address: federico@biol.unlp.edu.ar (F. Sisti).

<http://dx.doi.org/10.1016/j.bmcl.2016.12.049>

0960-894X/© 2016 Published by Elsevier Ltd.

The *Bordetella* LPS core presents one KDO molecule and two heptoses linked to lipid A. This composition is quite different from other LPSs where up to three heptoses are present. Only three genes, *waaA*, *waaC* and *waaF* are known to participate in the deep core synthesis.^{11,12} Guerten and co-workers described in *B. pertussis* four glycosyltransferases that participate in sugar core substitutions. However, no effects in *Bordetella* pathogenesis has been described for those mutants.¹³ We have previously reported that a deep rough LPS mutant is unable to establish an infection in wild type mice.¹² Interestingly, we suggested that early elimination may be the strong response to a deep rough LPS compared to smooth LPS. Particularly an enhanced IL-12 and TNF- α response was observed in mice treated with a deep rough LPS suggesting that distal portions of LPS are involved in host immune response regulation.¹²

We hypothesized that enzymes that catalyse the addition of hexoses to the growing core of *B. bronchiseptica* LPS would be similar to known glycosyltransferases from other bacteria. Therefore, we found genes dispersed around all the *B. bronchiseptica* RB50 genome as shown in Supplemental Table S1. Pan-genome analysis indicates that genes associated with diverse phenotypes, antibiotic resistance or that confer selective advantages are often found within the accessory genome rather than the core genome.¹⁴ Hester and co-workers suggested that horizontally acquired divergent O-antigen contributes to escape from cross-immunity in the classical *Bordetellae*.¹⁵ Dispersal position of these genes may suggest a possible source of LPS structure diversity between different *Bordetella* circulating strains. However, when other available genomes were analyzed, those genes were in the same relative position suggesting that glycosyltransferase genes are part of the core rather than accessory genome. Some of those genes are arranged in groups of putative glycosyltransferases. One of those groups, involving *BB3396* to *BB3400* are homologous to *BP2328* to *BP2331* previously described by Geurtsen and co-workers as glycosyltransferases involved in *B. pertussis* Tohama I LPS core synthesis.¹³ Moreover, a similar group of genes in *Burkholderia cenocepacia* were previously described.¹⁶ Interestingly, one of *B. cenocepacia* genes, *BCAL2407*, a glycosyltransferase presents homology to *BB3394*.

In order to confirm the role of this cluster of genes in LPS synthesis, we constructed mutants in *B. bronchiseptica* 9.73H⁺ with the individual genes *BB3394* and *BB3398* interrupted by an antibiotic resistance cassette. Wild type LPS presented a full length LPS with defined bands A and B and a diffuse low moving band corresponding to lipid A-core-O antigen structure. As expected, *Bb* Δ *BB3398* LPS showed in Fig. 1A a fast moving unique band corresponding to a truncated LPS.

On the other hand, *Bb* Δ *BB3394* LPS profile was indistinguishable from wild type LPS suggesting that deletion of genes involved in GlcN, GlcA or GalNA transfer to the core would not alter the length of the LPS (Fig. 1A). As a first approach to evaluate possible LPS modifications, sensitivity to naive serum were evaluated and compared to wild type strain. Interestingly, *Bb* Δ *BB3394* and *Bb* Δ *BB3398* did not grow properly in naive serum in contrast to *Bb*9.73H⁺ strain. Resistance to both agents was restored when *Bb* Δ *BB3394* mutant was complemented with the corresponding gene. Results are shown in Fig. 1B.

To get deeper into the LPSs structures, LPSs from each mutant strain were further purified. The corresponding oligosaccharides were released by acid hydrolysis and analyzed by mass spectrometry. The MALDI-MS spectrum of the *B. bronchiseptica* wild type 9.73H⁺ oligosaccharide in the reflectron positive ion mode using GA as matrix is presented in Fig. 2A and supplemental Fig. S1. In the high molecular weight range a signal at *m/z* 1637.0 (calc. *m/z* 1637.5537, C₅₉H₁₀₀N₅O₄₆Na) consistent with a core fragment containing (Hep)GlcN-(GalNA)Glc-(GlcAGlcNHep)Hep bearing a FucN




Fig. 1. LPS electrophoretic phenotype reveals modifications in *Bb* Δ *BB3398* but not in *Bb* Δ *BB3394* mutant (A). Silver-stained SDS-PAGE 17.5% wt/vol profiles of phenol-water-extracted LPS samples from *Bb*9.73H⁺ wild-type, *Bb* Δ *BB3394* mutant and *Bb* Δ *BB3398* mutant strains. Both mutants showed different susceptibility to naive sera (B). ~1000 CFU were exposed to naive sera at different proportions to SS media. Appropriate dilutions were plate in BG after 2 h at 37 °C. Results are expressed as percentage of CFU recovered when were exposed to SS media. * indicates *P* < 0.05; *Bb*9.73H⁺ versus mutant.




Fig. 2. MALDI-MS spectrum of the *B. bronchiseptica* wild type 9.73H⁺ (A) and *Bb* Δ *BB3394* mutant (B) oligosaccharide in the reflectron positive ion mode using GA as matrix.

unit from the distal trisaccharide is present. Ion at *m/z* 1594.5 (calc. *m/z* 1594.5353) would correspond to the loss of an acetyl group from the latter. In accordance, ion at *m/z* 1456.1 (calc *m/z* 1456.4319, C₅₁H₈₄N₃Na₂O₄₂) would correspond to the core octasaccharide fragment consistent with (Hep)GlcN-(GalNA)Glc-(GlcAGlcNHep)Hep as an oxonium ion. In addition loss of the GalNA unit from the latter gives rise to *m/z* 1259.7 (calc. *m/z* 1259.4019, C₄₅H₇₆N₂Na₂O₃₇), and signal at *m/z* 1085.3 (calc. *m/z* 1084.3656, C₃₈H₆₇N₃Na₂O₃₁) corresponds to the loss of GlcA and a Heptose unit from *m/z* 1456.1. In addition, species at *m/z* 1191.1 (calc. *m/z* 1190.4059, C₄₄H₇₀N₇Na₂O₂₉) is consistent with the distal trisaccha-

ride (GlcNAc-Man2,3NAcA-FucN) linked to the core fragment GlcN-(GalNA)Glc.

The MALDI-MS spectrum of the mutant *BB3394* strain oligosaccharide in the positive ion mode (Fig. 2B and supplemental Fig. S2) showed the highest mass species at m/z 1259.6 (calc. m/z 1260.4103, $C_{45}H_{77}N_2NaO_{37}$) and m/z 1281.6 (ΔNa) consistent with the core fragment (Hep)GlcN-Glc-(GlcNGlcAHep)Hep. The lack of higher m/z species would indicate the absence of the GalNA unit. In addition, ion at m/z 1153.0 (calc. m/z 1153.3997, $C_{42}H_{72}N_3NaO_{32}$) is consistent with a FucN-(Hep)GlcN-Glc-Hep-Kdo core fragment. Ions at m/z 1065.0 (calc. m/z 1064.2924, $C_{35}H_{61}N_3Na_2O_{29}P$) and m/z 1021.0 ($\Delta 44$) correspond to FucN-GlcN-Glc-Hep-KdoP fragment.

The MALDI-MS spectrum of the mutant *BB3394* strain, performed in the negative ion mode using *nor*-harmane as matrix (Fig. 3A and supplemental Fig. S3) showed a complex pattern of signals.

Ion at m/z 2281.2 (calc. m/z 2280.6719, $C_{79}H_{132}N_7O_{65}P_2^-$) corresponds to the core region consistent with (Hep)GlcN-Glc-(GlcNGlcAHep)Hep-KdoPP linked to the Band A trisaccharide GlcNAc-Man2,3NAcA-FucN. Ion at m/z 1706.9 (calc. m/z 1707.5860, $C_{64}H_{103}N_6O_{47}$) corresponds to Man2,3NAcA-FucNGlcN-Glc(GlcNGlcAHep)Hep-anhKdo. Furthermore, loss of the branching oligosaccharide constituted by (GlcN-Glc)Hep and a phosphate group from the latter renders ion at m/z 1130.6 (calc. m/z 1130.4104, $C_{42}H_{72}N_3O_{32}$). Signal at m/z 1840.1 (calc. m/z 1839.6312 $C_{68}H_{112}N_8O_{48}P$) would correspond to FucN linked to the Band A trisaccharide plus (Hep)GlcN-Glc-Hep-anhKdoP. Ion at m/z 1557.1 (calc. m/z 1557.6171, $C_{60}H_{101}N_8O_{39}$) may be due to prompt fragmentation of m/z 1840.1, causing the loss of anhKdoP. In addition, m/z 1272.2 (calc. m/z 1272.3325, $C_{42}H_{72}N_3O_{37}P_2$) is consistent with FucN-(Hep)GlcN-Glc-Hep-anhKdoPP. Furthermore, ion at m/z 1993.7 (calc. m/z 1994.7606, $C_{79}H_{124}N_{11}O_{48}$) corresponds to the fragment GlcNAc-Man2,3NAcA-FucN-GlcNAc-Man2,3NAcA-FucN-GlcN-Glc-Hep-anhKdo-H₂O; ion at m/z 2130.8

(calc. m/z 2131.6508, $C_{74}H_{125}N_8O_{59}P_2$) would correspond to the trisaccharide unit plus GlcN-Glc-(GlcAGlcNHep)Hep-Kdo-PPEA. In the low MW range, main ion at m/z 842.9 (calc. m/z 843.2051, $C_{28}H_{46}NO_{26}P$) may be attributed to the (GlcN-Hep)Hep-anhKdoP fragment. Interestingly no signals corresponding to fragments bearing the GalNA unit could be detected. Conservation of *BB3394* in sequenced *B. bronchiseptica* genomes suggests the importance of this substitution for bacteria normal physiology. Resistance to naive sera is a phenotype usually modified when LPS alterations are present. Long LPS structures avoid complement components to reach bacterial surface. However in our hands, a small modification like the absence of the branching GalNA was sufficient to alter resistance to sera.

In several *Bordetella* LPS, a pentasaccharide fragment that links the O-antigen to the core region has been identified.¹⁰ Previous reports indicated that the O-chain of these bacteria LPS was a linear homopolymer of 1,4-linked 2,3-dideoxy-2,3-diacetamido-L-galacturonic acid (L-Gal2,3NAcA).¹⁷ However, differences between the end groups on *B. bronchiseptica* O antigens were described such as the presence of a terminal residue (Lac-type, 328.3 Da, and Ala-type, 327.3 Da). Further studies revealed that a proportion of the O-polysaccharide repeating units are present as uronamide (L-Gal2,3NAcAN), the number of which varies between strains.¹⁰ Also, the presence in the O-antigen of blocks of amides and blocks of acids, whereas less abundant mixed amide/acid ions were evidenced.

In accordance, signals related to the O-antigen oligosaccharide were detected in the MALDI-MS spectrum of the mutant *BB3394* strain. Thus, ion peak at m/z 2848.1 (calc. m/z 2848.0675, $C_{111}H_{163}N_{28}O_{60}$) may be attributed to the O-antigen fragment built up of a terminal "Lac type" residue, three uronamide units (L-Gal2,3NAcAN), four 2,3-dideoxy-2,3-diacetamido-L-galacturonic acids (L-Gal2,3NAcA) and three monosaccharides from the linking pentasaccharide (Man2,3NAcAN-Glc2,3NAcAN-GalNAc) with the concomitant loss of water. Ion at m/z 2583.1 (calc. m/z 2582.0044, $C_{102}H_{155}N_{23}O_{55}$) was assigned to a fragment built up by two 2,3-dideoxy-2,3-diacetamido-L-galacturonic acids (L-Gal2,3NAcA) and one uronamide unit (L-Gal2,3NAcAN) linked to the pentasaccharide plus the Band A trisaccharide unit. Ion at m/z 2418.4 (calc. m/z 2418.9663, $C_{95}H_{150}N_{20}O_{53}$) is consistent with one uronamide unit linked to the pentasaccharide plus Band A trisaccharide plus Hep-GlcN. In addition, ion at m/z 1418.3 (calc. m/z 1418.5691, $C_{56}H_{86}N_{14}O_{29}$) is attributed to one uronamide unit linked to the pentasaccharide and ion at m/z 1178.9 (calc. m/z 1178.4706, $C_{46}H_{72}N_{11}O_{25}$) corresponds to the pentasaccharide unit.

In contrast, regarding mutant *BB3398*, the MALDI-MS spectrum of the released oligosaccharide, in the negative mode (Fig. 3B and supplemental Fig. S3) showed the highest mass ion at m/z 2287.9 (calc. m/z 2288.6883, $C_{80}H_{132}N_9O_{63}P_2$) as expected for the lack of the O-antigen structure suggested by SDS-PAGE. This ion corresponds to a GlcNAc-Man2,3NAcA-FucN-GlcN-(GalNA)Glc-(GlcNGlcAHep)Hep-anhKdoPPEtN structure. In addition, ion at m/z 1997.6 (calc. m/z 1998.5667 $C_{70}H_{114}N_7O_{58}P_2$) would correspond to Man2,3NAcA-FucN-GlcN-(GalNA)Glc-(GlcNGlcAHep)Hep-anhKdoPP after the loss of CO₂ (44 μ). Also ion at m/z 1561.1 (calc. m/z 1561.4569, $C_{54}H_{90}N_4O_{46}P$) corresponds to FucN-GlcN-(GalNA)Glc-(GlcAHep)Hep-KdoP. Furthermore, ions at m/z 1418.9 (calc. m/z 1419.4800 $C_{54}H_{87}N_4O_{42}$) and m/z 1463.5 ($\Delta 44$) are ascribed to FucN-GlcN-(GalNA)Glc-(GlcAHep)Hep-anhKdo. In all cases the GalNA unit linked to the Glc of the core region was present in this mutant.

Interestingly, absence of GalNA in *BB3394* mutant is not detrimental for distal structures synthesis. However, absence of lateral Heptose in *BB3398* LPS generated a rough LPS indicating that Heptose needs to be present to be recognize as a substrate for enzymes




Fig. 3. MALDI-MS spectrum of the mutant *BbABB3394* strain (A) and *BbABB3398* mutant (B) oligosaccharide performed in the negative ion mode.

involved in LPS synthesis. Similar observation was previously reported with core second heptose.¹¹ Deletion of *waaF* an heptosyl-transferase involved in second heptose addition generated a deep rough phenotype.

Once confirmed we have *B. bronchiseptica* LPS with deep modifications (deep rough LPS from BbLP39 and *Bb*ΔBB3398) or mildly modifications like *Bb*ΔBB3394 we hypothesized that structural differences will hold different immune responses. We have previously shown that a deep rough LPS triggers different interleukine responses in bone marrow derived dendritic cells.¹⁸

Dendritic cell response to smooth or complete *B. bronchiseptica* LPS is characterized by high TNF-alpha levels. Same response is observed when wild type LPS is instilled in naïve mice.¹⁹ Hence we evaluate if LPSs first described in the present work were able to elicit a TNF-alpha response. When LPS derived from BB3398 or BB3394 mutants were intranasally instilled in mice, differences were observed (Table 1).

Interestingly, deep rough LPS derived from *Bb*ΔBB3398 elicited non significantly differences to wild type LPS. However, we showed that GalNA substitution is important to induce TNF-alpha response. Absence of this lateral sugar in *B. bronchiseptica* LPS inhibits TNF-alpha response (Table 1). Interestingly, TNF-alpha is an important factor secreted during first steps of infection and its absence is detrimental to limitation of *B. bronchiseptica* infection.¹⁹

It has been suggested that LPS immune activity may be responsible for directing an appropriated protective response.^{20,21} Therefore, a previously tested vaccination schedule was used to evaluate protection capacity of the different LPSs here in described.²² Female three weeks old BALB/c mice were i.p. immunized with 5 µg of purified wild type LPS. As a control, whole cell formaldehyde inactivated vaccine was used to immunize mice. After 2 immunizations, mice were challenged intranasally with sublethal doses of wild type *B. bronchiseptica*. Five days after challenge, animals were sacrificed and the number of bacteria in lungs was determinate. As expected not immunized mice presented a high number in CFU/lung, while whole cell immunized mice were protected against infection progress (Fig. 4).

One of main components of whole cell vaccine is LPS. When mice were immunized with *B. bronchiseptica* wild type LPS no significantly differences were observed with mice immunized by whole cell (Fig. 4).

Protection induced by *B. bronchiseptica* LPS was genera and species specific. If we immunized with either *B. pertussis* or *E. coli* DH5α LPS, no protection was observed (Fig. 4). Both *E. coli* DH5α and *B. pertussis* LPS are short-chain LPS, commonly named lipooligosaccharide. Interestingly *B. pertussis* and *B. bronchiseptica* core structure showed no differences.

When mice were immunized with 5 µg of a deep rough LPS from BbLP39 mutant no protection was observed supporting that distal LPS portions are necessary to induce protection (Fig. 4).

Using the same vaccination and challenge schedule, purified LPS from *Bb*ΔBB3398 and *Bb*ΔBB3394 with confirmed structure changes were evaluated. As shown in Fig. 4, *Bb*ΔBB3398 deep rough LPS was not able to elicit a protective response in mice as the other deep rough LPS from BbLP39. Interestingly, LPS from *Bb*ΔBB3394 mutant, lacking the GalNA unit in the core, protects mice against infection as the wild type LPS. This result is in agree-




Fig. 4. Effect of systemic (i.p.) immunization with different LPS structures and challenged with wild type *Bb*9.73H* in C3H/HeN (black columns) or C3H/HeJ mice (grey columns). Statistical analysis was performed by ANOVA and Tukey test. * indicate significant differences with $p < 0.001$ respect to C3H/HeN mice.

ment to Buboltz and co-workers report. They showed that modifications in distal structures on O-antigen are sufficient to induce different protective responses.²³ Hence, even somehow core LPS structure can modify immune response, distal portions of LPS like O-antigen are necessary and sufficient to trigger a protective response. These results should be considered to develop a vaccine with cross protection between *Bordetella* species.

In conclusion, we have identified a new gene involved in the synthesis of the core LPS in *B. bronchiseptica*. Genes involved in distal LPS structure synthesis have been described previously. However, genes involved in core synthesis remains unknown probably due to dispersal location of genes through the genome. The core is a branched hetero-oligomer. Function of core lateral sugars are unknown. Here we presented first steps in function description, using LPS mutants with different core modifications.

We also demonstrated that LPS modifications correlates with reduction in resistance to naïve sera. In addition, differences in immune response to LPS were observed, however lateral modification GalNA was expendable to elicit protection against *B. bronchiseptica* infection. Further research is needed to establish role of all sugars present in *Bordetella* LPS. This knowledge will be necessary to design LPS containing vaccines.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

Funding

This work was supported by University of Buenos Aires, CONICET and the Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT). The Ultraflex II (Bruker) TOF/TOF mass spectrometer was supported by a grant from ANPCyT, PME 125. Authors are member of the Scientific Career of CONICET.

Table 1

Relative expression report generated by REST2009 after 2000 iterations.²⁴ Values are obtained after being normalized to alpha-actin levels and compared to levels observed in Bb 9.73H* LPS stimulated mice. P(H1): Probability of alternate hypothesis that difference between sample and control groups is due only to chance.

	TNF-alpha expression	Std. Error	P(H1)	Result vs Bb 9.73H*
LPS <i>Bb</i> ΔBB3398	0.556	0.271–1.180	0.138	
LPS <i>Bb</i> ΔBB3394	0.242	0.119–0.527	0.001	Down

Acknowledgments

This work was supported by National Agency for the Promotion of Science and Technology (ANCPyT) grants to D.F.H and AC. A.C., D. F.H., J.F. and F.S. are members of the Scientific Career of CONICET.

A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2016.12.049>.

References

1. Preston A, Mandrell RE, Gibson BW, Apicella MA. *Crit Rev Microbiol*. 1996;22:139–180.
2. Rietschel ET, Kirikae T, Schade FU, et al. *FASEB J*. 1994;8:217–225.
3. Trent MS, Stead CM, Tran AX, Hankins JV. *J Endotoxin Res*. 2006;12:205–223.
4. Harvey HA, Swords WE, Apicella MA. *J Autoimmun*. 2001;16:257–262.
5. Maskell DJ, Szabo MJ, Butler PD, Williams AE, Moxon ER. *Res Microbiol*. 1991;142:719–724.
6. de Vries FP, van Der Ende A, van Putten JP, Dankert J. *Infect Immun*. 1996;64:2998–3006.
7. Chmiela M, Miszczyk E, Rudnicka K. *World J Gastroenterol*. 2014;20:9882–9897.
8. Mann PB, Elder KD, Kennett MJ, Harvill ET. *Infect Immun*. 2004;72:6650–6658.
9. Le Blay K, Gueirard P, Guiso N, Chaby R. *Microbiology*. 1997;143:1433–1441.
10. Preston A, Petersen BO, Duus J, et al. *J Biol Chem*. 2006;281:18135–18144.
11. Allen AG, Isobe T, Maskell DJ. *J Bacteriol*. 1998;180:35–40.
12. Sisti F, Fernández J, Rodríguez ME, Lagares A, Guiso N, Hozbor DF. *Infect Immun*. 2002;70:1791–1798.
13. Geurtsen J, Dzieciatkowska M, Steeghs L, et al. *Infect Immun*. 2009;77:2602–2611.
14. Medini D, Donati C, Tettelin H, Masignani V, Rappuoli R. *Curr Opin Genet Dev*. 2005;15:589–594.
15. Hester SE, Park J, Goodfield LL, Feaga HA, Preston A, Harvill ET. *BMC Evol Biol*. 2013;13:209.
16. Ortega X, Silipo A, Saldías MS, Bates CC, Molinaro A, Valvano MA. *J Biol Chem*. 2009;284:21738–21751.
17. Vinogradov E, Peppler MS, Perry MB. *Eur J Biochem*. 2000;267:7230–7237.
18. Sisti F, Fernández J, Higgins SC, et al. *Microbiol Immunol*. 2011;55:847–854.
19. Mann PB, Wolfe D, Latz E, Golenbock D, Preston A, Harvill ET. *Infect Immun*. 2005;73:8144–8152.
20. Zhang X, Goebel EM, Rodríguez ME, Preston A, Harvill ET. *Infect Immun*. 2009;77:5050–5058.
21. Errea A, Moreno G, Sisti F, Fernández J, Rumbo M, Hozbor DF. *Med Microbiol Immunol*. 2010;199:103–108.
22. Roberts R, Moreno G, Bottero D, et al. *Vaccine*. 2008;26:4639–4646.
23. Wolfe DN, Buboltz AM, Harvill ET. *PLoS One*. 2009;4:e4280.
24. Pfaffl MW. *Nucl Acids Res*. 2001;29:e45.